Skip to main content
. 2021 Aug 13;12:691811. doi: 10.3389/fimmu.2021.691811

Figure 6.

Figure 6

TME-score is a prognostic biomarker and predicts immunotherapeutic benefit. (A) Intratumor heterogeneity in high and low TME-score. (B) TMB in high and low TME-score. (C) TIDE value and response to immunotherapy of patients with TME-scores. (D) Submap analysis based on the TIDE algorithm showed a significant difference in response to CTLA-4 and anti-PD-1 therapy with respect to the TME-score in TCGA. (E) TME-scores in groups with a response and non-response to anti–PD-1. Differences between groups were compared by the Wilcoxon test (Wilcoxon, P = 0.036). (F) Predictive value of the TME-score measured by ROC curves in the GSE35640 cohort. AUC is 0.657. (G) Kaplan–Meier curves for high and low TME-score patient groups in the GSE78220 cohort. Log-rank test, P = 0.00139. (H) TME-scores in groups with different anti–PD-1 clinical response status (CR/PR and SD/PD). Differences between groups were compared by Wilcoxon test (Wilcoxon, P = 0.019). (I) Rate of clinical response (CR/PR, SD/PD) to anti–PD-1 immunotherapy in high or low TME-score groups in the GSE78220 cohort. (J) Predictive value of the TME-score, PD-L1, and PD-L2 measured by ROC curves in the GSE78220 cohort. AUC is 0.742. Scatter plots depicting a positive correlation between TME-score and (K) CYT and (M) GEP. Pearson Correlation Coefficient R = 0.34 and 0.51, respectively. (L) CYT and (N) GEP expression differences in high and low TME-scores. Differences between groups were compared through the Wilcoxon test (Wilcoxon, P < 0.001).